HTG2014-Section-Header-publications

Categories

Filter by Topics

478P TA-ness ADCC Gene Alteration adolescents ALK Angiogenesis Anti-TNF Alpha Therapy antiEGFR Apoptosis apoptosis Asthma Autocrine Signaling Autoimmune Disorder B Cells benign Biofluid Biology of neoplasia Biomarker Analysis Biomarker Discovery Biomarker Validation Biomarkers Bladder Cancer Blood Brain Breast Cancer Breast milk cancer genetics Cancer Genomics Cardiovascular Disease CD3 CDKN2A mutation Cells Cerebrospinal Fluid Chemokines Childhood Atopic Dermatitis chronic kidney disease Chronic Obstructive Pulmonary Disease Circulating miRNAs circulating tumor classifications cMET Colorectal cancer Comparative Study Comparison study computational toxicology Core Needle Biopsy COVID-19 Custom mRNA cyclic AMP‑dependent transcription factor ATF‑4 Cytokines Cytotoxic T Cells cytotoxicity Dementia Developmental Immunotherapy Developmental Therapeutics Diabetes diabetic nephropathy Differential Expression Differential Gene Expression Analysis Diffuse Large B-Cell Lymphoma diffuse large B-cell lymphoma DLBCL DNA damage‑inducible transcript 3 protein DNA lymphoma Drug Response Drug Safety Drug Targets Drug-induced Liver Injury Efficacy EGFR Muatations EMT Encephalophy end stage kidney disease epidemiology epigenomics Epstein-Barr ERBB3 Esophageal Cancer Exosomes extracellular miRNAs Extracellular Vesicles Fabry Disease Feasibility FFPE FGF Ligand Trap FGFR Fibrous Tumors Follicular lymphoma GEIS Gene Expression gene expression Gene Expression Profiling gene expression profiling Gene Fusions Gene Signature Analysis Genetic Polymorphism Genitourinary cancer Glioblastoma Tumors Head and Neck Cancer Heart HER2 Histone Deacetylase Inhibitors HLA-E Homing HPV HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq DLBCL Cell of Origin Panel HTG EdgeSeq DLBCL-COO-CE-IVD HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Immuno-Oncology Panel HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq Lymphoma Panel HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq miRNA WTA HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Path Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq Precision Immunol-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel HTG EdgSeq Immuno-Oncology Assay ibrutinib Ibrutinib Immune Cells Immune Checkpoint Inhibitors Immune Related Genes Immune Response Immune System Immune Tolerance Immune-related Colitis Immuno-Oncology immunohistochemistry IHC IMMUNOSARC Immunotherapy Inflammation Integrins inverted papilloma ISG Juvenile Arthritis Kidney Liposarcoma Liquid Biopsy Liver liver tissue Lung Lung cancer Lupus Lymph Node Metastasis Lymphocytes Lymphoma lymphomas machine learning malignancy sinonasal malignant mCRC Mechanism of Action Melanoma Mesothelioma MET Method Comparison Microenvironment MicroRNA miRNA Molecular Characterization Mouse mRNA custom mTOR pathway mTOR signaling multi-omics multiple myeloma Multiple Myeloma Muscle mutation analysis Mutations MYC NAFLD Nash and Fibrosis native African men Natural Killer Cells Neoantigens Neuroendocrine Tumor Neurologic nivolumab non-Hodgkin Lymphoma Novel Therapeutic Targets NTRK1 Oesophageal Adenocarcinoma Oncology Oncology-Biomarker Oral Cancer Osteoarthritis Osteoclast Ovarian cancer Pancreas Paralysis Parkinson's Disease Pathogenesis Pathway Analysis Pathway analysis Patient Stratification PAXgene PBMCs PCA Cell Lines PD-1 PD-L1 PFAS PIK3CA mutation Placenta placenta Plasma Platform Comparison predictive biology Predictive Biomarkers Predictive Modeling Programmed cell death protein 1 Progression free-survival progression of renal failure Prostate Prostate Cancer prostate cancer prostate genomics Protein Protein Interaction network qNPA qPCR race disparities Radioimmunotherapy RAS Rearrangements Renal Cell Carcinoma Renal Disease Reproductive Response rate RET Reveal Rheumatoid Arthritis Risk Score ROS1 safety Sarcoma sarcoma Serum Signaling Inhibitors Signaling Pathways Signature Validation Signatures Sinonasal Carcinoma Skin soft tissue sarcoma SPECS Lung Consortium squamous cell carcinoma Squamous cell carcinoma Sub-typing surface plasmon Surveillance Survival Outcomes Survival plots Synovial Fluid synthetic miRNA T-Cell T-cells Technology Comparison Therapeutic Response Therapeutic targets Thymic Carcinoma Thyroid Cancer TMB tomentosin Toxicity TP53 mutation Translational Medicine Transplantation Treatment Outcome Treatment Stratification Treatment Targets Tumor Biology Tumor Heterogeneity Tumor Immunobiology Tumor infiltrating lymphocytes tumor microenvironment Tumor Microenvironment Urine Urothelial carcinoma Uterus VEGFR Wound healing Xenograft Tissue Zanubrutinib

2020

Comparison of immunohistochemical and gene expression profiling based subtype identification of diffuse large B-cell lymphoma. Focus on extranodal lymphoma

Tiemann, A., et al. Comparison of immunohistochemical and gene expression profiling based subtype identification of diffuse large B-cell lymphoma. Focus on extranodal lymphoma. Poster and Abstract 263 presentedDeutsche Gesellschaft Fur Hamatologie Und Medizinische Onkologie.  at Virtual Annual Meeting 2020 OCT 9 - 11. 

View External Link

Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined replapsed or refractory diffuse large B-cell lymphoma

Lenz, G., et al. Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined replapsed or refractory diffuse large B-cell lymphoma. Leukemia 2020 (34) 2184-2197. https://doi.org/10.1038/s41375-020-0743-y

Download pdf 848KB

Small Cell Lung Cancer Neuroendocrine Subtypes are Associated with Different Immune Microenvironment and Checkpoint Molecule Distribution

Dora, D., et al. Small Cell Lung Cancer Neuroendocrine Subtypes are Associated with Different Immune Microenvironment and Checkpoint Molecule Distribtution. bioRxiv preprint 2020 Feb 3. doi:https://doi.org/10.1101/2020.02.02.930305

Download pdf 3.4MB

Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Woment with Treatment-Naïve Metastatic Breast Cancer

Finn, R. S., et al. Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Woment with Treatment-Naïve Metastatic Breast Cancer. Clinical Cancer Research | Precision Medicine and Imaging. 2020 Jan 15. 26:110-21. DOI: 10.1158/1078-0432.CCR-19-0751.

Download pdf 1.4MB

2019

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Younes, A., et al. Journal of Clinical Oncology 2019 Mar22;37(15):1285-1295. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.

Download pdf 1.2MB

Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006)

Martin, M., et al., Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs). Paper presented at San Antonio Breast Cancer Symposium; 2019 December 10-14; San Antonio, Texas. Session GS2.

Download pdf 1.1MB

Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with baseline Metabolic Tumor volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial.

Richter, J., et al. Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with Baseline Metabolic Tumor Volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial. Blood Cancer Journal 2019 Aug 19; 9(67).

Download pdf 757KB

Transcriptomic and Protein Analysis of Small-cell Baldder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target.

Koshkin, V. S., et al. Transcriptomic and Protein Analysis of Small-cell Bladder Cancer  Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. Clinical Cancer Research. 2019 Jan 1; 25(1) 210-221.

Download pdf 7.4MB

2018

Comparison of Immunohistochemistry Assay Results with Gene Expression Profiling Methods for Diffuse Large B-Cell Lymphoma Subtype Identification in Matched Patient Samples.

Schaffer, M., et al. Comparison of Immunohistochemistry Assay Results with Gene Expression Profiling Methods for Diffuse Large B-Cell Lymphoma Subtype Identification in Matched Patient Samples. J Mol Biomark Diagn 2018, 9:2 DOI: 10.4172/2155-9929.1000386

Download pdf 1.3MB

Page last updated January 06, 2022